PROCEPT BioRobotics Faces Class Action Over Sales Tactics

PROCEPT BioRobotics Corporation (NASDAQ: PRCT) is the subject of a securities class action lawsuit filed by Kaplan Fox & Kilsheimer LLP. The complaint targets stock purchases made between February 28, 2024, and February 25, 2026. Investors who suffered losses during this period are eligible to participate in the proposed class, with a lead plaintiff deadline set for September 22, 2026.

According to the filing, the company’s reported financials were misleading due to undisclosed sales tactics. The lawsuit claims that PROCEPT’s discount program caused handpiece unit orders to consistently exceed actual procedures throughout the class period. This discrepancy allegedly pulled future demand forward, artificially boosting current quarter revenues while distorting the true trajectory of product utilization.

Alleged Manipulation of Sales Data

The core of the allegation centers on the divergence between unit sales and procedure counts. PROCEPT had previously assured the market that the differential between these two metrics had remained relatively consistent. However, the complaint asserts that internal data showed a material breach of this consistency. By incentivizing dealers to purchase handpieces at a discount, the company allegedly accelerated order volume without a corresponding increase in clinical usage.

This strategy effectively borrowed revenue from future periods to meet current targets. The plaintiffs argue that such practices violate securities laws by presenting a false picture of the company's operational health. The distortion is attributed specifically to the U.S. market, where these sales tactics were most prevalent during the specified two-year window.

Lead Plaintiff Deadline Looms

The court has set September 22, 2026, as the final date for potential class members to move for appointment as lead plaintiff. While seeking this role is not required to share in any eventual recovery, it determines the law firm managing the case. Kaplan Fox & Kilsheimer LLP, which filed the initial complaint, is currently representing the proposed class. The firm has a history of handling large-scale securities litigation, including cases involving major financial institutions.

Investor Eligibility and Next Steps

Eligibility for the class is limited to those who purchased PROCEPT common stock during the defined period. The lawsuit does not require individuals to have sold their shares at a loss to qualify, though damages are typically calculated based on the decline in value. Investors are advised to monitor court filings for updates on the lead plaintiff motion. Participation in the class action is automatic for eligible shareholders unless they opt out, but the outcome depends on the court's acceptance of the allegations.